Bridging the Gaps in Proteomics
Affinity-based protein analysis tools have become increasingly scalable, expanding their established use in low-plex settings. Nomic is the latest entrant in this space with its nELISA™ technology, which aims to unlock greater scale and versatility. GEN spoke with
Milad Dagher, PhD, CEO and co-founder of Nomic, about how the nELISA platform is transforming proteomics.
GEN: What are key factors influencing the broader adoption of proteomics technologies?
Given the central role of proteins in biology, many believe proteomics has the potential to surpass genomics in its impact on life sciences and healthcare. In recent years, targeted investments and large-scale datasets like the U.K. Biobank Pharma Proteomics Project have demonstrated its power for biomarker discovery.
However, most scientists are still relying on conventional tools. For proteomics to reach its full potential, three hurdles must be cleared: affordability to enable well-powered studies, quantification to support AI-driven insights and data interoperability, and plex flexibility to facilitate downstream applications. Solving these challenges will push proteomics from a specialized tool a cornerstone in life science research and drug development.
GEN: How does Nomic’s nELISA platform bridge these gaps?
We started with a simple question: What would it take to make proteomics scalable, affordable, and quantitative? The key was to reimagine the sandwich immunoassay while keeping the solution simple. That led to nELISA, a platform that integrates DNA nanotechnology with bead-based immunoassays and high-throughput cytometry.
A major challenge in scaling multiplexed immunoassays is cross-reactivity from antibody mixing. Traditional methods struggle with this, and proximity-based approaches reduce it but at the expense of increased variability from amplification steps. nELISA eliminates cross-reactivity entirely by pre-assembling antibody pairs on individual beads and using a displacement-based detection. This results in exquisite specificity, which, when combined with the precision of bead-based assays, enables absolute quantification even at high plex.
nELISA isn’t just high-plex—it’s flexible. Researchers can measure a broad range of proteins, from comprehensive panels to focused selections, without compromise.
The result is a simple, robust, and highly quantitative proteomics platform.
GEN: What do Nomic’s offerings look like today?
As a step toward building a proteome-wide panel, we started with the largest quantitative inflammation panel—275 proteins—designed for broad applications in early drug discovery, novel therapeutic modalities, and translational research.
With our à la carte target selection offering, scientists can transition from exploratory studies to custom-built panels with minimal development time. We’re also actively expanding our library into new research areas, so stay tuned for more updates!
We prioritize providing researchers with a seamless analysis experience and the ability to utilize their data for rapid insights and decision-making. To support this, we have developed an end-to-end service that accelerates large-scale protein profiling while reducing costs and time. Additionally, the Nomic Portal facilitates rapid analysis, visualization, and streamlined data interpretation.
GEN: What types of research are unlocked by more accessible proteomics technology, like nELISA?
The strength of the nELISA platform lies in its applicability across various modalities.
In drug discovery, nELISA’s high throughput and cost efficiency are already enabling next-gen AI-powered target discovery. nELISA is currently widely adopted for large-scale functional genomics screens, as well as target and phenotype identification.
In pre-clinical phases—where midplex panels were traditionally used—nELISA’s comprehensive inflammatory panel and flexible down-scaling capabilities facilitate the elucidation of mechanisms of action and the identification of toxicology biomarkers.
Finally, in biomarker discovery, nELISA enables well-powered studies and data interoperability, supporting the identification of more reliable markers for early response and disease prognosis.
Nomic was founded to make biology easier to measure and enable scientists to extend lives. We’re doing that one application at a time, and we’re just getting started.
See the full content on GEN
Get Started
Ready to explore? Or have questions?
Our nELISA experts are a few clicks away!
Bridging the Gaps in Proteomics
Subscribe to Updates
Affinity-based protein analysis tools have become increasingly scalable, expanding their established use in low-plex settings. Nomic is the latest entrant in this space with its nELISA™ technology, which aims to unlock greater scale and versatility. GEN spoke with
Milad Dagher, PhD, CEO and co-founder of Nomic, about how the nELISA platform is transforming proteomics.
GEN: What are key factors influencing the broader adoption of proteomics technologies?
Given the central role of proteins in biology, many believe proteomics has the potential to surpass genomics in its impact on life sciences and healthcare. In recent years, targeted investments and large-scale datasets like the U.K. Biobank Pharma Proteomics Project have demonstrated its power for biomarker discovery.
However, most scientists are still relying on conventional tools. For proteomics to reach its full potential, three hurdles must be cleared: affordability to enable well-powered studies, quantification to support AI-driven insights and data interoperability, and plex flexibility to facilitate downstream applications. Solving these challenges will push proteomics from a specialized tool a cornerstone in life science research and drug development.
GEN: How does Nomic’s nELISA platform bridge these gaps?
We started with a simple question: What would it take to make proteomics scalable, affordable, and quantitative? The key was to reimagine the sandwich immunoassay while keeping the solution simple. That led to nELISA, a platform that integrates DNA nanotechnology with bead-based immunoassays and high-throughput cytometry.
A major challenge in scaling multiplexed immunoassays is cross-reactivity from antibody mixing. Traditional methods struggle with this, and proximity-based approaches reduce it but at the expense of increased variability from amplification steps. nELISA eliminates cross-reactivity entirely by pre-assembling antibody pairs on individual beads and using a displacement-based detection. This results in exquisite specificity, which, when combined with the precision of bead-based assays, enables absolute quantification even at high plex.
nELISA isn’t just high-plex—it’s flexible. Researchers can measure a broad range of proteins, from comprehensive panels to focused selections, without compromise.
The result is a simple, robust, and highly quantitative proteomics platform.
GEN: What do Nomic’s offerings look like today?
As a step toward building a proteome-wide panel, we started with the largest quantitative inflammation panel—275 proteins—designed for broad applications in early drug discovery, novel therapeutic modalities, and translational research.
With our à la carte target selection offering, scientists can transition from exploratory studies to custom-built panels with minimal development time. We’re also actively expanding our library into new research areas, so stay tuned for more updates!
We prioritize providing researchers with a seamless analysis experience and the ability to utilize their data for rapid insights and decision-making. To support this, we have developed an end-to-end service that accelerates large-scale protein profiling while reducing costs and time. Additionally, the Nomic Portal facilitates rapid analysis, visualization, and streamlined data interpretation.
GEN: What types of research are unlocked by more accessible proteomics technology, like nELISA?
The strength of the nELISA platform lies in its applicability across various modalities.
In drug discovery, nELISA’s high throughput and cost efficiency are already enabling next-gen AI-powered target discovery. nELISA is currently widely adopted for large-scale functional genomics screens, as well as target and phenotype identification.
In pre-clinical phases—where midplex panels were traditionally used—nELISA’s comprehensive inflammatory panel and flexible down-scaling capabilities facilitate the elucidation of mechanisms of action and the identification of toxicology biomarkers.
Finally, in biomarker discovery, nELISA enables well-powered studies and data interoperability, supporting the identification of more reliable markers for early response and disease prognosis.
Nomic was founded to make biology easier to measure and enable scientists to extend lives. We’re doing that one application at a time, and we’re just getting started.
See the full content on GEN
Get Started
Ready to explore? Or have questions?
Our nELISA experts are a few clicks away!
Bridging the Gaps in Proteomics
Affinity-based protein analysis tools have become increasingly scalable, expanding their established use in low-plex settings. Nomic is the latest entrant in this space with its nELISA™ technology, which aims to unlock greater scale and versatility. GEN spoke with
Milad Dagher, PhD, CEO and co-founder of Nomic, about how the nELISA platform is transforming proteomics.
GEN: What are key factors influencing the broader adoption of proteomics technologies?
Given the central role of proteins in biology, many believe proteomics has the potential to surpass genomics in its impact on life sciences and healthcare. In recent years, targeted investments and large-scale datasets like the U.K. Biobank Pharma Proteomics Project have demonstrated its power for biomarker discovery.
However, most scientists are still relying on conventional tools. For proteomics to reach its full potential, three hurdles must be cleared: affordability to enable well-powered studies, quantification to support AI-driven insights and data interoperability, and plex flexibility to facilitate downstream applications. Solving these challenges will push proteomics from a specialized tool a cornerstone in life science research and drug development.
GEN: How does Nomic’s nELISA platform bridge these gaps?
We started with a simple question: What would it take to make proteomics scalable, affordable, and quantitative? The key was to reimagine the sandwich immunoassay while keeping the solution simple. That led to nELISA, a platform that integrates DNA nanotechnology with bead-based immunoassays and high-throughput cytometry.
A major challenge in scaling multiplexed immunoassays is cross-reactivity from antibody mixing. Traditional methods struggle with this, and proximity-based approaches reduce it but at the expense of increased variability from amplification steps. nELISA eliminates cross-reactivity entirely by pre-assembling antibody pairs on individual beads and using a displacement-based detection. This results in exquisite specificity, which, when combined with the precision of bead-based assays, enables absolute quantification even at high plex.
nELISA isn’t just high-plex—it’s flexible. Researchers can measure a broad range of proteins, from comprehensive panels to focused selections, without compromise.
The result is a simple, robust, and highly quantitative proteomics platform.
GEN: What do Nomic’s offerings look like today?
As a step toward building a proteome-wide panel, we started with the largest quantitative inflammation panel—275 proteins—designed for broad applications in early drug discovery, novel therapeutic modalities, and translational research.
With our à la carte target selection offering, scientists can transition from exploratory studies to custom-built panels with minimal development time. We’re also actively expanding our library into new research areas, so stay tuned for more updates!
We prioritize providing researchers with a seamless analysis experience and the ability to utilize their data for rapid insights and decision-making. To support this, we have developed an end-to-end service that accelerates large-scale protein profiling while reducing costs and time. Additionally, the Nomic Portal facilitates rapid analysis, visualization, and streamlined data interpretation.
GEN: What types of research are unlocked by more accessible proteomics technology, like nELISA?
The strength of the nELISA platform lies in its applicability across various modalities.
In drug discovery, nELISA’s high throughput and cost efficiency are already enabling next-gen AI-powered target discovery. nELISA is currently widely adopted for large-scale functional genomics screens, as well as target and phenotype identification.
In pre-clinical phases—where midplex panels were traditionally used—nELISA’s comprehensive inflammatory panel and flexible down-scaling capabilities facilitate the elucidation of mechanisms of action and the identification of toxicology biomarkers.
Finally, in biomarker discovery, nELISA enables well-powered studies and data interoperability, supporting the identification of more reliable markers for early response and disease prognosis.
Nomic was founded to make biology easier to measure and enable scientists to extend lives. We’re doing that one application at a time, and we’re just getting started.
See the full content on GEN
Download resource
Get Started
Ready to explore? Or have questions?
Our nELISA experts are a few clicks away!
Bridging the Gaps in Proteomics
Affinity-based protein analysis tools have become increasingly scalable, expanding their established use in low-plex settings. Nomic is the latest entrant in this space with its nELISA™ technology, which aims to unlock greater scale and versatility. GEN spoke with
Milad Dagher, PhD, CEO and co-founder of Nomic, about how the nELISA platform is transforming proteomics.
GEN: What are key factors influencing the broader adoption of proteomics technologies?
Given the central role of proteins in biology, many believe proteomics has the potential to surpass genomics in its impact on life sciences and healthcare. In recent years, targeted investments and large-scale datasets like the U.K. Biobank Pharma Proteomics Project have demonstrated its power for biomarker discovery.
However, most scientists are still relying on conventional tools. For proteomics to reach its full potential, three hurdles must be cleared: affordability to enable well-powered studies, quantification to support AI-driven insights and data interoperability, and plex flexibility to facilitate downstream applications. Solving these challenges will push proteomics from a specialized tool a cornerstone in life science research and drug development.
GEN: How does Nomic’s nELISA platform bridge these gaps?
We started with a simple question: What would it take to make proteomics scalable, affordable, and quantitative? The key was to reimagine the sandwich immunoassay while keeping the solution simple. That led to nELISA, a platform that integrates DNA nanotechnology with bead-based immunoassays and high-throughput cytometry.
A major challenge in scaling multiplexed immunoassays is cross-reactivity from antibody mixing. Traditional methods struggle with this, and proximity-based approaches reduce it but at the expense of increased variability from amplification steps. nELISA eliminates cross-reactivity entirely by pre-assembling antibody pairs on individual beads and using a displacement-based detection. This results in exquisite specificity, which, when combined with the precision of bead-based assays, enables absolute quantification even at high plex.
nELISA isn’t just high-plex—it’s flexible. Researchers can measure a broad range of proteins, from comprehensive panels to focused selections, without compromise.
The result is a simple, robust, and highly quantitative proteomics platform.
GEN: What do Nomic’s offerings look like today?
As a step toward building a proteome-wide panel, we started with the largest quantitative inflammation panel—275 proteins—designed for broad applications in early drug discovery, novel therapeutic modalities, and translational research.
With our à la carte target selection offering, scientists can transition from exploratory studies to custom-built panels with minimal development time. We’re also actively expanding our library into new research areas, so stay tuned for more updates!
We prioritize providing researchers with a seamless analysis experience and the ability to utilize their data for rapid insights and decision-making. To support this, we have developed an end-to-end service that accelerates large-scale protein profiling while reducing costs and time. Additionally, the Nomic Portal facilitates rapid analysis, visualization, and streamlined data interpretation.
GEN: What types of research are unlocked by more accessible proteomics technology, like nELISA?
The strength of the nELISA platform lies in its applicability across various modalities.
In drug discovery, nELISA’s high throughput and cost efficiency are already enabling next-gen AI-powered target discovery. nELISA is currently widely adopted for large-scale functional genomics screens, as well as target and phenotype identification.
In pre-clinical phases—where midplex panels were traditionally used—nELISA’s comprehensive inflammatory panel and flexible down-scaling capabilities facilitate the elucidation of mechanisms of action and the identification of toxicology biomarkers.
Finally, in biomarker discovery, nELISA enables well-powered studies and data interoperability, supporting the identification of more reliable markers for early response and disease prognosis.
Nomic was founded to make biology easier to measure and enable scientists to extend lives. We’re doing that one application at a time, and we’re just getting started.
See the full content on GEN
Get Started
Ready to explore? Or have questions?
Our nELISA experts are a few clicks away!